The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict RTI Biologics's revenues will wither -11.5% and EPS will wane -50.0%.
The average estimate for revenue is $38.7 million. On the bottom line, the average EPS estimate is $0.02.
Last quarter, RTI Biologics logged revenue of $44.6 million. GAAP reported sales were 3.9% higher than the prior-year quarter's $42.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.04. GAAP EPS of $0.04 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 48.8%, 260 basis points better than the prior-year quarter. Operating margin was 8.0%, 40 basis points worse than the prior-year quarter. Net margin was 5.1%, 40 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $178.8 million. The average EPS estimate is $0.17.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 210 members out of 222 rating the stock outperform, and 12 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 44 give RTI Biologics a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.96.
Is RTI Biologics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add RTI Biologics to My Watchlist.